Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with...

Source: AIDS Research and Therapy - September 9, 2023 Category: Infectious Diseases Authors: Frank Mulindwa, Barbara Castelnuovo, Nele Brusselaers, Martin Nabwana, Robert Bollinger, Allan Buzibye, Eva Laker Agnes Odongpiny, Ronald Kiguba and Jean-Marc Schwarz Tags: Research Source Type: research